STOCK TITAN

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Starlight Therapeutics, a subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), announced the formation of its Scientific Advisory Board (SAB) to support the development of STAR-001 for CNS and brain tumors. The inaugural SAB includes four distinguished experts: Dr. Mitchel S. Berger from UCSF, Dr. Lisa M. DeAngelis from Memorial Sloan Kettering, Dr. Stuart Grossman from Johns Hopkins Kimmel Cancer Center, and Dr. John Laterra from Johns Hopkins. These experts will provide strategic guidance for developing treatments targeting both adult and pediatric CNS cancers.

Starlight Therapeutics, una filiale di Lantern Pharmaceuticals (NASDAQ: LTRN), ha annunciato la creazione del suo Consiglio Consultivo Scientifico (SAB) per supportare lo sviluppo di STAR-001 per tumori del sistema nervoso centrale e del cervello. Il SAB inaugurale include quattro esperti di fama: Dr. Mitchel S. Berger della UCSF, Dr. Lisa M. DeAngelis del Memorial Sloan Kettering, Dr. Stuart Grossman del Johns Hopkins Kimmel Cancer Center e Dr. John Laterra sempre dal Johns Hopkins. Questi esperti forniranno indicazioni strategiche per lo sviluppo di terapie mirate ai tumori del SNC negli adulti e nei bambini.

Starlight Therapeutics, una subsidiaria de Lantern Pharmaceuticals (NASDAQ: LTRN), anunció la formación de su Consejo Asesor Científico (SAB) para apoyar el desarrollo de STAR-001 para tumores del sistema nervioso central y cerebrales. El SAB inaugural incluye a cuatro expertos distinguidos: Dr. Mitchel S. Berger de UCSF, Dr. Lisa M. DeAngelis del Memorial Sloan Kettering, Dr. Stuart Grossman del Johns Hopkins Kimmel Cancer Center, y Dr. John Laterra también de Johns Hopkins. Estos expertos proporcionarán orientación estratégica para desarrollar tratamientos dirigidos a cánceres del SNC en adultos y niños.

Starlight TherapeuticsLantern Pharmaceuticals (NASDAQ: LTRN)의 자회사로서, CNS 및 뇌종양에 대한 STAR-001 개발을 지원하기 위해 과학 자문 위원회(SAB)를 구성했다고 발표했습니다. 창립 SAB는 네 명의 저명한 전문가로 구성되어 있습니다: Mitchel S. Berger 박사 (UCSF), Lisa M. DeAngelis 박사 (Memorial Sloan Kettering), Stuart Grossman 박사 (Johns Hopkins Kimmel Cancer Center), 그리고 John Laterra 박사 (Johns Hopkins)입니다. 이 전문가들은 성인 및 소아 CNS 암을 겨냥한 치료법 개발을 위한 전략적 지침을 제공할 것입니다.

Starlight Therapeutics, une filiale de Lantern Pharmaceuticals (NASDAQ: LTRN), a annoncé la formation de son Conseil Consultatif Scientifique (SAB) pour soutenir le développement de STAR-001 pour les tumeurs du SNC et du cerveau. Le SAB inaugural comprend quatre experts éminents : Dr. Mitchel S. Berger de l'UCSF, Dr. Lisa M. DeAngelis du Memorial Sloan Kettering, Dr. Stuart Grossman du Johns Hopkins Kimmel Cancer Center et Dr. John Laterra également de Johns Hopkins. Ces experts fourniront des orientations stratégiques pour le développement de traitements ciblant à la fois les cancers du SNC chez les adultes et les enfants.

Starlight Therapeutics, eine Tochtergesellschaft von Lantern Pharmaceuticals (NASDAQ: LTRN), gab die Gründung ihres Wissenschaftlichen Beirats (SAB) bekannt, um die Entwicklung von STAR-001 für ZNS- und Gehirntumore zu unterstützen. Der einführende SAB umfasst vier angesehene Experten: Dr. Mitchel S. Berger von der UCSF, Dr. Lisa M. DeAngelis vom Memorial Sloan Kettering, Dr. Stuart Grossman vom Johns Hopkins Kimmel Cancer Center und Dr. John Laterra von Johns Hopkins. Diese Experten werden strategische Anleitungen zur Entwicklung von Behandlungen für sowohl erwachsene als auch pädiatrische ZNS-Krebserkrankungen bereitstellen.

Positive
  • Formation of high-profile Scientific Advisory Board with renowned experts in neuro-oncology
  • Strategic expertise addition for STAR-001 development in CNS and brain tumors
  • Access to combined experience from leading cancer centers (UCSF, MSKCC, Johns Hopkins)
Negative
  • None.

DALLAS--(BUSINESS WIRE)-- Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight’s management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and brain tumors for both children and adults.

“The establishment of the SAB represents a significant advancement for Starlight, and we are honored to be joined by such accomplished scientific experts. We look forward to drawing upon the deep subject matter expertise of Drs. Berger, DeAngelis, Grossman and Laterra, to shape the development path of STAR-001,” said Dr. Marc Chamberlain, M.D., Starlight’s Chief Medical Officer. “We also extend congratulations to Drs. Berger and Grossman on being recipients of the prestigious Lifetime Achievement Award from the Society of Neuro-oncology. Congratulations!”

The SAB includes (in alphabetical order):

- Dr. Mitchel S. Berger, M.D., is the chair of the Department of Neurosurgery, director of the Brain Tumor Center, director of Center for Neurological Injury and Repair and, co-director of Adult Brain Tumor Surgery Program at UCSF. Dr. Berger is a nationally recognized expert in treating brain and spinal cord tumors and tumor-related epilepsy in adults and children. He is a specialist in brain mapping techniques to identify and preserve motor, sensory and language function during surgery and, an expert in using Gamma Knife, a precise, noninvasive radiation beam tool for tumor treatment. Dr. Berger has completed American Cancer Society fellowships in neuro-oncology at UCSF, research fellowship by the Brain Tumor Research Center, and in pediatric neurosurgery at the Hospital for Sick Children at University of Toronto. Dr. Berger was elected to American Association of Neurological Surgeons' board of directors and appointed to American Board of Neurological Surgery.

https://profiles.ucsf.edu/mitchel.berger

- Dr. Lisa M. DeAngelis, M.D., is the Chief Physician Executive and Scott M. and Lisa G. Stuart Chair at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. DeAngelis oversees all clinical services, research, medical education, and multi-center collaborations, including the 500-bed Memorial Hospital, 13 outpatient facilities, and seven regional care sites across NY and NJ. Dr. DeAngelis is an internationally recognized expert in brain cancer and neurological complications of cancer treatment, including cognitive impairment and stroke. Dr. DeAngelis served as chair of the Department of Neurology at MSKCC from 1997 to 2018, and co-founded MSK’s Brain Tumor Center, where experts from across MSKCC work to bring discoveries from the lab to patients. Dr. DeAngelis’ research has focused on primary brain tumors and led clinical trials to investigate new tumor therapies. Dr. DeAngelis has helped to develop the current regimen to treat primary CNS lymphoma, has authored over 350 peer-reviewed manuscripts, 130 book chapters and has written or edited eight books. Dr. DeAngelis is an elected member of National Academy of Medicine, fellow and former Vice Chair of American Neurological Association (ANA) and fellow of American Academy of Neurology (AAN), which in 2019 awarded her the organization’s highest honor, the Wartenberg Lecture.

https://www.mskcc.org/profile/lisa-deangelis

- Dr. Stuart Grossman, M.D., is Professor of Oncology at the Johns Hopkins Kimmel Cancer Center, is co-Leader of the Brain Cancer Program and has directed the clinical and research neuro-oncology efforts at Johns Hopkins since 1981. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded Phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many Phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs.

https://profiles.hopkinsmedicine.org/provider/stuart-grossman/2707207

- Dr. John Laterra, MD, Ph.D., is a Professor of Neurology, Oncology and Neuroscience and Co-Director of the Brain Cancer Disease Group at the Johns Hopkins Kimmel Cancer Center. Dr. Laterra is internationally recognized for his clinical expertise and research on mechanisms of brain tumor malignancy, tumor vascular biology and the identification of new therapeutic targets in gliomas. Dr. Laterra’s research focuses on the diagnosis and treatment of patients with primary brain tumors and neurological complications of systemic cancer and is funded by the National Institutes of Health and numerous private foundations.

https://profiles.hopkinsmedicine.org/provider/john-j-laterra/2706899

About Starlight Therapeutics:

Starlight Therapeutics is a wholly owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN). Lead program is STAR-001, a unique blood-brain barrier permeable small molecule that utilizes its powerful mechanism of action and synthetic lethality to exploit common vulnerabilities in CNS cancers with DNA damage repair (DDR) deficiencies. STAR-001 has the potential to be the first new drug for treating GBM since 2003. The anti-tumor potential of STAR-001 has been demonstrated across an extensive number of in-vitro and in-vivo CNS cancer models, including GBM, brain metastases, atypical teratoid rhabdoid tumors (ATRT) and, has been presented at leading conferences and publications including: Society for Neuro-Oncology annual meeting, American Association for Cancer Research annual meeting, and Frontiers in Drug Discovery Journal.

Please find more information at:

Investor and Media Contact:

IR@starlightthera.com

Source: Lantern Pharma Inc.

FAQ

Who are the members of Starlight Therapeutics' new Scientific Advisory Board?

The inaugural SAB members are Dr. Mitchel S. Berger (UCSF), Dr. Lisa M. DeAngelis (MSKCC), Dr. Stuart Grossman (Johns Hopkins), and Dr. John Laterra (Johns Hopkins).

What is the purpose of Starlight Therapeutics' Scientific Advisory Board for LTRN?

The SAB will provide strategic guidance and expert insights for the development of STAR-001 in CNS and brain tumors for both children and adults.

What is STAR-001 being developed for by Starlight Therapeutics (LTRN)?

STAR-001 is being developed as a treatment for CNS and brain tumors, targeting both pediatric and adult patients.

Lantern Pharma Inc.

NASDAQ:LTRN

LTRN Rankings

LTRN Latest News

LTRN Stock Data

33.00M
9.20M
14.75%
24.1%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DALLAS